Get started
YANTAI DONGCHENG BYY

YANTAI DONGCHENG B

13.18CNYD
+0.05+0.38%
At close at 07:00 GMT
CNY
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

002675 fundamentals

Key facts

Market capitalization‪11.12 B‬CNY
Dividend yield (indicated)0.61%
Price to earnings Ratio (TTM)58.91
Basic EPS (TTM)0.22CNY
Founded1998
Employees (FY)‪2.47 K‬
CEOZhi Gang Luo
Websitedcb-group.com
About

Yantai Dongcheng Biochemicals Co., Ltd. engages in the research, development, production and sales of heparin sodium bulk drug and chondroitin sulfate. The company main product series include API, Preparation and Nuclide Drug Series. It manufactures active pharmaceutical ingredient, nuclear medicine, chemical synthetic drugs and modern Chinese medicines. The company’s products include heparin, chondroitin sulphate, marine collagen, hyaluronic acid, glucosamine, heparinoid and cytochrome C. Yantai Dongcheng Biochemicals was founded on December 31, 1998 and is headquartered in Yantai, China.

Ownership
‪‪765.74 M‬‬
Free Float shares
‪‪572.80 M‬‬ (74.8%)
Closely held shares
‪‪192.94 M‬‬ (25.2%)
Free Float shares
‪‪572.80 M‬‬ (74.8%)
Closely held shares
‪‪192.94 M‬‬ (25.2%)
Capital structure
Market cap
‪‪11.12 B‬‬
Debt
‪‪2.26 B‬‬
Minority interest
‪‪891.02 M‬‬
Cash & equivalents
‪‪904.51 M‬‬
Enterprise value
‪‪13.37 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪11.12 B‬‬
Price to earning ratio (P/E)
58.91x
Price to sales ratio (P/S)
3.82x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
58.91x
Price to sales ratio (P/S)
3.82x
Valuation ratios
‪0.00‬
‪1.20‬
‪2.40‬
‪3.60‬
‪4.80‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪35.00‬
‪70.00‬
‪105.00‬
‪140.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−12%‬
‪−6%‬
‪0%‬
‪6%‬
‪12%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−260.00 M‬‬
‪0.00‬
‪‪260.00 M‬‬
‪‪520.00 M‬‬
‪‪780.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−250.00 M‬‬
‪0.00‬
‪‪250.00 M‬‬
‪‪500.00 M‬‬
‪‪750.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Active Pharmaceutical Ingredient
Nuclear Medicine
Preparation
Other
By country
Period: 2024
China
Overseas
Thailand

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬
Actual
Estimate
Earnings
Next:Apr 25, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪0.04‬
‪0.08‬
‪0.12‬
‪0.16‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
35.89%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
1.33%
Last payment
0.05
Last ex-date
Dec 19, 2024
Dividend history
‪0.65%‬
‪0.81%‬
‪0.97%‬
‪1.13%‬
‪1.29%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.07‬
‪0.14‬
‪0.21‬
‪0.28‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−800.00 M‬‬
‪0.00‬
‪‪800.00 M‬‬
‪‪1.60 B‬‬
‪‪2.40 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪1.60 B‬‬
‪‪3.20 B‬‬
‪‪4.80 B‬‬
‪‪6.40 B‬‬
Assets
Liabilities